# Sustaining HIV/TB Epidemic Control in South Africa under the President's Emergency Plan for AIDS Relief (PEPFAR)

Source: https://welltoldgrants.com/grants/cdc-rfa-gh21-2126-sustaining-hiv-tb-epidemic-control-in-south-africa/  
Official notice: https://www.grants.gov/search-results-detail/329101

> Centers for Disease Control - CGH offered grants to any type of organization. It expected to make about 6 awards. Applications closed on April 20, 2021.

| Field | Value |
|---|---|
| Opportunity number | CDC-RFA-GH21-2126 |
| Agency | Centers for Disease Control - CGH |
| Status | Forecast |
| Deadline | April 20, 2021 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 6 |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.067 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $200,000,000 for Year 1, subject to the availability of funds. For this NOFO, CDC strongly encourages applicants to apply to the Average One Year Award Amount/Approximate Average Award amount of $50,000,000 instead of applying to the full $200,000,000 Approximate Total Fiscal Year Funding amount for Year 1. Applicants should develop a proposal to spend $50,000,000 carrying out activities in 2 sample districts (1 high-burden district and 1 low-burden district) in South Africa. Exact funding amounts and the geographic scope for each award under this NOFO will be determined at the time of award. South Africa (SA) is home to both the largest HIV burden and the largest HIV treatment program in the world. It is also a country with high rates of TB, HIV/TB, and multi-drug resistant TB (MDR-TB). Though the South African Government (SAG) has made significant headway improving the availability of HIV and TB services over the past 20 years, significant challenges remain in meeting and sustaining targets for epidemic control and ensuring all persons residing in SA are able to access quality services. The goal of this NOFO is to identify partners to support the SAG in providing quality HIV and TB treatment services and targeted prevention services to persons living with or at risk for HIV and/or TB. Key interventions will be those that directly impact the Joint United Nations Program on HIV/AIDS (UNAIDS) 95-95-95 cascade for people living with HIV (PLHIV) and support achievement of the targets for TB elimination described in the World Health Organization (WHO) End TB Strategy. Additional health system strengthening activities will be included to enable the government to provide better HIV/TB services or support the process of transitioning key HIV/TB response activities to the SA National Department of Health (NDOH).Recipients of this NOFO will be expected to work in geographies where CDC currently supports HIV/TB care and treatment services with the flexibility of changing to other districts based on future PEPFAR country operational plan (COP) negotiations and decisions.

## Questions people ask

### Is CDC-RFA-GH21-2126 still open?

No. It closed on April 20, 2021.

### Who can apply for Sustaining HIV/TB Epidemic Control in South Africa under the President's Emergency Plan for AIDS Relief (PEPFAR)?

Centers for Disease Control - CGH accepted applications from any type of organization.

### What is the deadline for Sustaining HIV/TB Epidemic Control in South Africa under the President's Emergency Plan for AIDS Relief (PEPFAR)?

Closed April 20, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has won Global AIDS grants before?

The largest recipients over five fiscal years were The Trustees of Columbia University in the City of New York, Elizabeth Glaser Pediatric AIDS Foundation, Management and Development for Health. The program made 521 awards worth $7.6 billion in that time.